Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
narcolepsy
Pharma
With $2.37B offer, Alkermes sweetens deal to acquire Avadel
Facing the fact that Lundbeck’s unexpected offer for Avadel was sweeter, Alkermes has upped its bid to acquire the sleep specialist.
Fraiser Kansteiner
Nov 19, 2025 9:53am
Lundbeck looks to buy Avadel from under Alkermes with $2.25B bid
Nov 14, 2025 9:29am
To enter sleep market, Alkermes forks over $2.1B for Avadel
Oct 22, 2025 12:04pm
China biotech deals, Takeda, LaNova—Fierce Pharma Asia
Jul 18, 2025 9:04am
Axsome will begin trial this year in MDD with daytime sleepiness
Apr 1, 2025 4:40pm
JPM25: Takeda touts 6 pipeline assets with big sales potential
Jan 15, 2025 3:17pm
